Ouro Fino Saúde Animal Participações (OFSA3) Q2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2024 earnings summary
1 Sep, 2026Executive summary
Revenue excluding Foot-and-Mouth Disease (FMD) vaccine grew 7.3% in 2Q24 and 7.0% in 6M24, driven by strong performance in production and companion animal segments despite challenging market conditions and the FMD vaccination campaign's cancellation in Brazil.
Launched innovative products, including Ferappease for cattle and pigs, and approved two new swine vaccines for launch in the second half of 2024.
Profitability improved with gross margin, EBITDA margin, and net margin all expanding, supported by efficiency gains and cost discipline.
International operations faced revenue declines, mainly due to FMD vaccine discontinuation and challenging conditions in Mexico, though Colombia performed well.
No significant economic impact from Rio Grande do Sul floods on business operations.
Financial highlights
Net revenue for Q2 2024 was R$231 million (BRL), with R$27 million from FMD; adjusted revenue grew 7.3% YoY, and gross margin improved to 48.2% in Q2 2024 and 51.2% YTD ex-FMD.
Adjusted EBITDA for 6M24 rose 51.3% YoY to R$57.0 million, with margin up 5.0 p.p.; net income for H1 2024 reached R$29.7 million, reversing a prior-year loss.
Operating cash flow generation was R$100 million in 6M24, and cash and equivalents increased to R$343.2 million as of June 2024.
Net debt reduced by 47.3% YoY to R$67.5 million, with leverage dropping to 0.4x EBITDA.
SG&A expenses remained flat or declined YoY, reflecting ongoing cost discipline.
Outlook and guidance
Confident in meeting commercial and financial targets for the year, with expectations of further margin and revenue growth as new products are launched and plant capacity is optimized.
Two new vaccines for the pig market approved and scheduled for launch in the second semester.
Continued focus on cost control, innovation, and international expansion, particularly in Latin America.
No significant operational impacts identified from the Rio Grande do Sul climate event as of the report date.
Latest events from Ouro Fino Saúde Animal Participações
- Innovation-driven animal health leader with strong growth and broad LATAM market presence.OFSA3
Company presentation - Net revenue rose 31.3% to R$589.1m in H1 2026, with strong profit and cash flow growth.OFSA3
Q2 2026 - Double-digit revenue and margin growth in Q3 2024, led by new products and efficiency.OFSA3
Q3 2024 - Net revenue up 26.1% in 4Q24, with record profitability and seven new product launches.OFSA3
Q4 2024 - Revenue up 6.3% YoY, but margins and net income fell on higher costs and capital reduction.OFSA3
Q1 2025 - 2Q25 revenue up 19.3%, EBITDA up 26.5%, led by production animals and capital returned to shareholders.OFSA3
Q2 2025 - Net revenue up 26.2% and EBITDA up 30.6%, with strong cash generation and innovation-led growth.OFSA3
Q3 2025 - Net revenue rose 19.5% and net income surged, supported by innovation and international growth.OFSA3
Q4 2025 - Net revenue up 32.1% to R$250.5m, gross profit up 46.9%, and EBITDA up 139.0%.OFSA3
Q1 2026